News
FWPAY
400.00
NaN%
--
Weekly Report: what happened at FWPAY last week (0226-0301)?
Weekly Report · 03/04 10:49
Weekly Report: what happened at FWPAY last week (0219-0223)?
Weekly Report · 02/26 10:59
Weekly Report: what happened at FWPAY last week (0212-0216)?
Weekly Report · 02/19 11:01
Weekly Report: what happened at FWPAY last week (0205-0209)?
Weekly Report · 02/12 10:52
Weekly Report: what happened at FWPAY last week (0129-0202)?
Weekly Report · 02/05 10:59
Weekly Report: what happened at FWPAY last week (0122-0126)?
Weekly Report · 01/29 10:50
Weekly Report: what happened at FWPAY last week (0115-0119)?
Weekly Report · 01/22 10:53
Weekly Report: what happened at FWPAY last week (0108-0112)?
Weekly Report · 01/15 10:50
Weekly Report: what happened at FWPAY last week (0101-0105)?
Weekly Report · 01/08 10:53
Weekly Report: what happened at FWPAY last week (1225-1229)?
Weekly Report · 01/01 10:49
Weekly Report: what happened at FWPAY last week (1218-1222)?
Weekly Report · 12/25/2023 10:58
Weekly Report: what happened at FWPAY last week (1211-1215)?
Weekly Report · 12/18/2023 11:03
More
Webull provides a variety of real-time FWPAY stock news. You can receive the latest news about Forward Pharma A/S through multiple platforms. This information may help you make smarter investment decisions.
About FWPAY
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.